Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 6 from your keywords: subject="Type 2 Diabetes"
cover
Vildagliptin modulates the microbiota and induces an immunometabolic profile …
Comment Share
de Macedo JCC

Dipeptidyl peptidase 4 (DPP-4) inhibitors (DPP-4i) are widely used to treat Type 2 diabetes (T2D) and are known for their cardiovascular and renal safety profiles. Systematic reviews have also shown that DPP-4i are associated with reduced dementia risk via unknown mechanisms. To examine vildagliptin (DPP-4i) effects on the intestinal microbiota in T2D patients, plasma metabolomics were conducte…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Dapagliflozin: A Review in Type 2 Diabetes
Comment Share
Dhillon S

Dapagliflozin ( Forxiga®) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as add-on combination therapy (with other glucose-lowering agents, including insulin) for …

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diab…
Comment Share
Henry RR

Combining metformin (XR) with dapagliflozin to initiate pharmacotherapy in patients with type 2 diabetes (T2D) and high baseline HbA1c may be advantageous. We conducted two randomised, double-blind, three-arm 24-week trials in treatment-naı¨ve patients to compare dapagliflozin plus metformin, dapagliflozin alone and metformin alone.

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitra…
Comment Share
Kim HS

To compare the efficacy and safety of early combination therapy with glimepiride/metformin to metformin uptitration in reducing glycated hemoglobin (HbA1c) levels in Korean type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy.

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Glimepiride : A Review of its Use in the Management of Type 2 Diabetes Mellitus
Comment Share
Langtry HD

Glimepiride is a sulphonylurea agent that stimulates insulin release from pancreatic b-cells and may act via extrapancreatic mechanisms. It is administered once daily to patients with type 2 (non–insulin-dependent) diabetes mellitus in whom glycaemia is not controlled by diet and exercise alone, and may be combined with insulin in patients with secondary sulphonylurea failure

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
The pathophysiologic basis of efficacy and clinical experience with the new o…
Comment Share
Rosak C

Type 2 diabetes results from the abnormal resistance of peripheral tissues to insulin and from the progressive insulin secretory failure of the pancreatic b-cells. Treatment of type 2 diabetes has greatly improved due to the availability of new classes of oral antidiabetic drugs (OADs) and new insulin analogs. Three types of oral medications exert their antidiabetic action without directly stim…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-